Data Insights

Enfortumab vedotin by Astellas Pharma for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase III for Transitional Cell Carcinoma (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)

Data Insights

Enfortumab vedotin by Astellas Pharma for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Enfortumab vedotin by Astellas Pharma for Peritoneal Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Peritoneal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Peritoneal Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Fallopian Tube Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Fallopian Tube Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Fallopian Tube Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Epithelial Ovarian Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Epithelial Ovarian Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC)....

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Muscle Invasive Bladder Cancer (MIBC)

Data Insights

Enfortumab vedotin by Astellas Pharma for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Enfortumab vedotin by Astellas Pharma for Gastric Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Gastric Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Non-Small Cell Lung Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Non-Small Cell Lung Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Esophageal Cancer: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Esophageal Cancer

Data Insights

Enfortumab vedotin by Astellas Pharma for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase III for Transitional Cell Cancer (Urothelial Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Transitional Cell Cancer (Urothelial Cell Cancer)

Data Insights

Enfortumab vedotin by Astellas Pharma for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Enfortumab vedotin by Astellas Pharma for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Enfortumab vedotin by Astellas Pharma for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase I for Non Muscle Invasive Bladder Cancer...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)

Data Insights

Enfortumab vedotin by Astellas Pharma for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Human Epidermal Growth Factor Receptor...

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

Data Insights

Enfortumab vedotin by Astellas Pharma for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Enfortumab vedotin is under clinical development by Astellas Pharma and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....

Likelihood of Approval and Phase Transition Success Rate Model - Enfortumab Vedotin in Esophageal Squamous Cell Carcinoma (ESCC)